Estimates from the World Alzheimer Report 2021 indicate that nearly 75% of dementia cases across the globe are undiagnosed. This highlights the need for robust biomarkers for screening and diagnosing individuals with neurodegenerative disorders.
There is currently a lack of effective treatments for neurodegenerative conditions like Alzheimer’s disease and Parkinson’s disease, and early diagnoses may help delay or prevent these conditions.
Individuals with Alzheimer’s or Parkinson’s begin to show sleep disturbances and changes in brain activity levels during sleep from the early stages of these conditions. Thus, brain activity patterns during sleep could be used as biomarkers for neurodegenerative conditions.
